1,5-DIPHENYL-3-PYRIDINYLAMINO-1,5-DIHYDROPYRROLIDIN-2-ONE AS CB1 RECEPTOR MODULATOR
申请人:Schaus John Mehnert
公开号:US20100016375A1
公开(公告)日:2010-01-21
Compound and pharmaceutical compositions of Formula by blockade of the CB
1
receptors via an inverse agonism mechanism, and are useful for reducing body weight in mammals, cognitive impairment associated with schizophrenia, mitigating treatment emergent weight gain observed during treatment with antipsychotics and have increased bioavailability.
1, 5-DIPHENYL-3-BENZYLAMINO-1, 5-DIHYDROPYRROLIDIN-2-ONE AS CB1 RECEPTOR MODULATORS
申请人:Coffey David Scott
公开号:US20090275618A1
公开(公告)日:2009-11-05
Compounds and pharmaceutical compositions of Formula (I) by blockade of the CB
1
receptors via an inverse agonism mechanism which are useful for reducing body weight in mammals, cognitive impairment associated with schizophrenia, mitigating treatment emergent weight gain observed during treatment with antipsychotics and have increased bioavailability.
1, 5-diphenyl-3-benzylamino-1, 5-dihydropyrrolidin-2-one as CB1 receptor modulators
申请人:Eli Lilly and Company
公开号:US08168659B2
公开(公告)日:2012-05-01
Compounds and pharmaceutical compositions comprising compounds of the Formula
as CB1 receptor inverse agonists useful for reducing body weight in mammals, treating cognitive impairment associated with schizophrenia, and mitigating treatment emergent weight gain observed during treatment with antipsychotics.
1,5-diphenyl-3-pyridinylamino-1,5-dihydropyrrolidin-2-one as CB1 receptor modulator
申请人:Eli Lilly and Company
公开号:US07998985B2
公开(公告)日:2011-08-16
Compound and pharmaceutical compositions comprising the compounds of the Formula
or a pharmaceutically acceptable salt thereof, as a CB1 receptor inverse agonist, useful for reducing body weight in mammals, treating cognitive impairment associated with schizophrenia, and mitigating treatment emergent weight gain observed during treatment with antipsychotics.